May 6, 2021
Hospira recalls one lot each of 0.5% Bupivacaine and 1% Lidocaine because of mislabeling
Editor's Note
Hospira Inc, a Pfizer company, announced May 4 that it is recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCL Injection, USP 30 mL because of mislabeling.
A portion of each lot was incorrectly labeled as the other product. The issue was identified by a customer.
Use of the impacted products could cause adverse events of moderate to high severity.
Free Daily News
- Kentucky Derby, SPD race: Leadership lessons energized SPD professionals at HSPA 2025
- Continuum-based protocol offers new strategy for preventing PONV after thyroidectomy
- Pembrolizumab sets new standard in advanced head and neck cancer surgery, trial shows
- Subarachnoid spinal anesthesia offers safe, effective option for high-risk obstetric patients
- Same-day discharge after catheter ablation gains backing from top cardiology societies
- Tenet, HCA post strong Q1 results, but caution looms over policy uncertainty, outpatient trends
- Telemedicine transforms postoperative care through safer, faster, patient-centered recovery
- ASCA conference coverage to keep ASC leaders informed
- Study: Prolonged COVID symptoms more likely for healthcare workers
- Study: Patients of female surgeons experience fewer complications, lower long-term readmission
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement